SCHEMBL6139633

SCHEMBL6139633

C=C(C)OCCCCOC(=C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.44
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 1/20 0.36
CA12 O43570 3/20 0.35
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA9 Q16790 3/20 0.35
NAAA Q02083 1/20 0.33
TDP1 Q9NUW8 3/20 0.32
POLB P06746 1/20 0.32
APEX1 P27695 1/20 0.32
HTT P42858 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 2/20 0.32
EPHX1 P07099 1/20 0.31
THRB P10828 1/20 0.31
ACHE P22303 4/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9497231 0.89
SCHEMBL10071490 0.89 ALDH1A1 (0.39) TSHRALDH1A1CYP3A4CA12CA1
SCHEMBL1155676 0.89
SCHEMBL8978821 0.87 TSHR (0.63) TSHRALDH1A1CA12CA1CA2
SCHEMBL11798288 0.87 TSHR (0.63) TSHRALDH1A1CA12CA1CA2
SCHEMBL10071496 0.87 ALDH1A1 (0.43) TSHRALDH1A1CYP3A4CA12CA1
SCHEMBL18807559 0.87
SCHEMBL5703187 0.87 TSHR (0.42) TSHRALDH1A1CYP3A4NAAATDP1
SCHEMBL9498948 0.87 TSHR (0.63) TSHRALDH1A1CA12CA1CA2
SCHEMBL11810777 0.87 TSHR (0.63) TSHRALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017189953-A1 POLY(KETALS) AND RELATED COMPOSITIONS AND METHODS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2017-11-02 WO disclosed
EP-1240139-B1 METHOD FOR PRODUCING N-ALKENYL AMIDES BASF AG (DE) 2005-11-09 EP disclosed
US-6624303-B2 By reacting the corresponding NH-amides with acetylenes in the liquid phase using a basic alkali metal compound as catalyst and as cocatalyst (di- or tri-)1,4-butanediol mono- and diethers; N-vinyl-2-pyrrolidone from pyrrolidone BASF AKTIENGESELLSCHAFT (DE) 2003-09-23 US disclosed
EP-1268380-B1 METHOD FOR PRODUCING ALKENYL ETHERS BASF AG (DE) 2003-09-17 EP disclosed
US-20030114715-A1 Method for producing alkenyl ethers BOETTCHER ARND (DE) 2003-06-19 US disclosed
US-20030028035-A1 Method for producing n-alkenyl amides BASF AKTIENGESELLSCHAFT (DE) 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030028035-A1 Method for producing n-alkenyl amides NAT1, H1-2, H1-0 TSHR 2175/4885ALDH1A1 472/4885CYP3A4 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.